Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Chemmedchem|November 23, 2012
3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitorYi-Yu Ke, Hui-Yi Shiao, Yung Chang Hsu, et al.Bioorganic & Medicinal Chemistry Letters|June 26, 2012
3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)John T-A Hsu, Teng-Kuang Yeh, Shih-Chieh Yen, et al.Journal of Medicinal Chemistry|April 25, 2013
Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitorsYi-Hui Peng, Hui-Yi Shiao, Chih-Hsiang Tu, et al.Chemmedchem|December 30, 2009
Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitorMohane Selvaraj Coumar, Ming-Tsung Tsai, Chang-Ying Chu, et al.Bioorganic Chemistry|March 16, 2020
Drug-like property optimization: Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitorsShu-Yu Lin, Chun-Feng Chang, Mohane Selvaraj Coumar, et al.European Journal of Medicinal Chemistry|June 18, 2015
Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutationsChiung-Tong Chen, John T-A Hsu, Wen-Hsing Lin, et al.Bioorganic & Medicinal Chemistry|April 27, 2013
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)Wen-Hsing Lin, John T-A Hsu, Shu-Yi Hsieh, et al.Journal of Medicinal Chemistry|July 2, 2013
Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitorHui-Yi Shiao, Mohane Selvaraj Coumar, Chun-Wei Chang, et al.Journal of Medicinal Chemistry|September 9, 2015
Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual ScreeningJian-Sung Wu, Shu-Yu Lin, Fang-Yu Liao, et al.Journal of Medicinal Chemistry|February 7, 2023
Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung CancerMu-Chun Li, Mohane Selvaraj Coumar, Shu-Yu Lin, et al.Pageof 3